Chemokine to the Rescue: Interleukin-8 Mediates Resistance to PI3K-Pathway-Targeted Therapy in Breast Cancer
Menée sur des lignées cellulaires et des modèles murins de cancer du sein triplement négatif, cette étude suggère que l'inhibition de la signalisation JAK2/STAT5 permet de surmonter l'apparition d'une résistance à un inhibiteur de la signalisation PI3K/mTOR
Adaptive resistance to PI3K-mTOR inhibitors potentially limits the clinical antitumor activities of these agents. In this issue of Cancer Cell, Britschgi and coworkers show that certain tumors acquire resistance to PI3K-mTOR inhibitors through activation of a JAK2-dependent pathway, leading to interleukin-8 secretion.
Cancer cell , commentaire, 2011